Therapy with anti-PD-L1 immune check-point inhibitors is approved for several cancers, including advanced urothelial carcinomas. PD-L1 prevalence estimates vary widely in bladder cancer, and lack of ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する